Drug-Induced Liver Injury
Idiosyncratic liver injury associated with drugs (ILIAD)
Enrollment status: OPEN
The goal of the ILIAD protocol is to create a database and bank of biological specimens (DNA, plasma, lymphocytes) from individuals with severe drug-induced liver injury (DILI) due to isoniazid (INH), phenytoin (Dilantin), amoxicillin/ clavulanate (Augmentin), valproic acid (Depakote), nitrofurantoin, quinolone antibiotics, tetracycline, and sulfa drugs after January 1, 1994. This study is funded by the NIH/NIDDK.
Study design
- Telephone or personal interview of medical history surrounding DILI event
- Single blood draw
- Participant receives $75
A multi-center, longitudinal study of drug- and CAM-induced liver injury
Enrollment Status: OPEN
The goal of this multicenter NIH study is to prospectively identify bona fide cases of liver injury due to drugs and complementary and alternative medications (CAM) within 6 months of onset. Clinical data, blood, DNA, and urine will be collected from affected patients and matched controls for mechanistic and genetic studies.
Study Design
- All subjects have a baseline and 6-month follow-up visit at the University of Michigan Health System, which includes surveys, medical history, and blood and urine collection.
- Patients with liver injury at 6 months return for 12- and 24-month visits.
Costs
- Costs of study lab tests provided by sponsor (NIDDK).
- Subjects receive $50 for each completed study visit.
Contacts for referrals or questions:
For more information on drug-induced liver injury see the following web sites:
Drug-Induced Liver Injury Network: http://dilin.dcri.duke.edu/index.html
NIH funds network to study drug-induced liver injury: http://www.nih.gov/news/pr/nov2004/niddk-19.htm
